ESSA Pharma Inc. (EPIX) Stock Analysis & Investment Frameworks
ESSA Pharma Inc. (EPIX) stock analysis on Invetso. Review ESSA Pharma Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
ESSA Pharma Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
ESSA Pharma Inc. Key Financial Metrics
- Market Cap: $9.52M
- Revenue: $N/A
- ROE: -21.12%
- ROIC: -27.55%
- Dividend Yield: N/A
About ESSA Pharma Inc.
ESSA Pharma Inc. (EPIX) functions as a clinical-stage pharmaceutical firm, concentrating its efforts on developing innovative and exclusive therapies designed to combat prostate cancer. The company's primary drug candidate is EPI-7386, an oral treatment presently undergoing Phase I clinical trials. This investigational compound is intended for individuals suffering from metastatic castration-resistant prostate cancer. Furthermore, ESSA Pharma has established collaborative partnerships with organizations including Caris Life Sciences, Inc., Bayer Consumer Care AG, Janssen Research & Development, LLC, and Astellas Pharma Inc. Founded in 2009, the company's corporate offices are located in Vancouver, Canada.